

Henrik AgersÃ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11914288/publications.pdf>

Version: 2024-02-01

28
papers

1,686
citations

516710
16
h-index

526287
27
g-index

28
all docs

28
docs citations

28
times ranked

1424
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and Adults. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1217-1226.	3.5	4
2	Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 567-576.	3.6	19
3	Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 969-977.	4.4	5
4	A Population Pharmacokinetic Model for Concizumab Based on Phase 1 and Phase 2 Trial Data. <i>Blood</i> , 2020, 136, 4-4.	1.4	0
5	Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials. <i>Clinical Pharmacokinetics</i> , 2019, 58, 63-75.	3.5	24
6	Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 196-203.	4.0	2
7	The kidneys play a central role in the clearance of rhGH in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 86, 29-33.	4.0	5
8	The kidneys play an important role in the clearance of rFVIIa in rats. <i>Thrombosis Research</i> , 2014, 133, 1124-1129.	1.7	3
9	Nephrectomized and Hepatectomized Animal Models as Tools in Preclinical Pharmacokinetics. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 75-86.	2.5	3
10	Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia. <i>Haemophilia</i> , 2012, 18, 6-10.	2.1	3
11	Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin. <i>British Journal of Haematology</i> , 2011, 152, 99-107.	2.5	17
12	Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 42, 578-583.	4.0	8
13	Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma. <i>Thrombosis and Haemostasis</i> , 2010, 104, 157-164.	3.4	16
14	Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 648-664.	2.4	30
15	Semi-Mechanistic Pharmacodynamic Modeling for Degarelix, a Novel Gonadotropin Releasing Hormone (GnRH) Blocker. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 609-634.	1.8	20
16	Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1204-1211.	2.0	53
17	Stochastic Differential Equations in NONMEM®: Implementation, Application, and Comparison with Ordinary Differential Equations. <i>Pharmaceutical Research</i> , 2005, 22, 1247-1258.	3.5	54
18	Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 352-358.	2.4	66

#	ARTICLE	IF	CITATIONS
19	Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations. Computer Methods and Programs in Biomedicine, 2004, 76, 31-40.	4.7	52
20	Population Pharmacokinetic Modeling of a Subcutaneous Depot for GnRH Antagonist Degarelix. Pharmaceutical Research, 2004, 21, 574-584.	3.5	25
21	Pharmacokinetic/Pharmacodynamic Modelling of GnRH Antagonist Degarelix: A Comparison of the Non-linear Mixed-Effects Programs NONMEM and NLME. Journal of Pharmacokinetics and Pharmacodynamics, 2004, 31, 441-461.	1.8	12
22	Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. European Journal of Pharmaceutical Sciences, 2003, 19, 141-150.	4.0	59
23	The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. European Journal of Pharmaceutical Sciences, 2003, 20, 335-340.	4.0	12
24	Pharmacokinetics and Pharmacodynamics of a New Formulation of Recombinant Human Growth Hormone Administered by ZomaJet 2 Vision, a New Needle-Free Device, Compared to Subcutaneous Administration Using a Conventional Syringe. Journal of Clinical Pharmacology, 2002, 42, 1262-1268.	2.0	30
25	Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes. Diabetes, 2002, 51, 424-429.	0.6	275
26	Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects. Diabetes Care, 2002, 25, 1398-1404.	8.6	272
27	Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration. Journal of Medicinal Chemistry, 2000, 43, 1664-1669.	6.4	591
28	Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 1999, 16, 1412-1416.	3.5	26